CULTURAL PROPERTIES OF THE SOUTH AFRICAN VARIANT OF OMICRON VIRUS SARS-CoV-2 OF CORONAVIRUS INFECTION COVID-19

this paper presents data on the study of the cultural properties of the genetic variant Omicron of the SARS-CoV-2 virus of the coronavirus infection COVID-19. The most permissive biological systems for the reproduction of this virus variant are Vero, MA-104, MARC-145, PK-15, and SPEV cell cultures. The productive conditions for cultivating the genetic variant Omicron of the SARS-CoV-2 virus in the studied cell lines turned out to be the following parameters: seeding concentration of cells 200 thousand/cm3, multiplicity of infection – 0.01 TCD50/cell, virus cultivation period – 2 days, cell lesion area monolayer before collecting the virus – 75-80%, the biological activity of the virus in the range from 4.14±0.31 to 6.66±0.22 lg TCD50/cm 3.

1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) (англ.). ArcGIS. Johns Hopkins University. -URL: https://coronavirus.jhu.edu/map.html (Дата обращения: 2022-11-17).

2. COVID-19 Coronavirus pandemic. https://www.worldometers.info/coronavirus (Дата обращения:2022-11-17).

3. Pachetti M., Marini B., Benedetti F., Giudici F., Mauro E., Storici P., Masciovecchio C., Angeletti S.et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. – 2020. – Vol.18 (1). – 179 p. doi: 10.1186/s12967-020-02344-6.

4. Zhang L., Jackson C.B., Mou H. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. – 2020. – Vol.11 (1). – 6013 p.

5. Намазова-Баранова Л.С., Садеки Н., Эфендиева К.Е. Новые данные по эволюции пандемии COVID-19: обзор литературы. Педиатрическая фармакология. – 2021. – Vol. 18. – P. 314-9. doi: 10.15690/ pf.v18i4.2299.

6. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // The Lancet. – 2020. – Vol. 395. – № 10223. – P. 467-506.

7. Jin Y., Yang H., Ji W. et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. – 2020. – Vol.12(4). – 372 р. doi:10.3390/ v12040372.

8. Relative Variant Genome Frequency per Region. https://www.gisaid. org/hcov19-variants. WHO. COVID-19 vaccine tracker and landscape [Электронный ресурс]. – 2022. (дата обращения 17.11.2022). https: //www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate -vaccines

9. Классификация варианта Омикрон (B.1.1.529) как варианта вируса SARS-CoV-2, вызывающего обеспокоенность. https: //www.who.int/ru/news/item/classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.

10. Forchette L.A. Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics/ L. Forchette, W. Sebastian, T. Liu // Curr Med Sci. – 2021. – Vol. 41, – № 6. – P. 1037-1051. doi: 10.1007/s11596- 021-2395-1.

11. Torjesen I. COVID-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ. – 2021. – Vol. 375. – 2943 р. doi:10.1136/bmj.n2943.

12. Nyberg T., Ferguson N.M., Nash S.G. et al. Comparative analysis of the risks of hospitalisation and death associated with SARSCoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. – 2022. – Vol.399. – Р. 1303-12. doi:10.1016/S0140-6736(22)00462-7.

13. Araf Y., Akter F., Tang Y.D. et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. – 2022. – Vol.94(5). – Р. 1825-32. doi:10.1002/jmv.27588.

14. Reed L.J., Muench Simple H. A. Method Of Estimating Fifty Per Cent Endpoints12 // American Journal of Epidemiology. – 1938. – Vol. 27. – P. 493-497. https://doi.org/10.1093/oxfordjournals. aje.a118408(1938).

15. Новикова И.А. Генетическая характеристика вируса SARS-CoV-2 / И. А. Новикова // Живые и биокосные системы. – 2021. – № 35. – 4 с. doi: 10.18522/2308- 9709-2021-35-4

16. Kaptelova V.V., Bukharina A.Y., Shipulina O.Y., Korneenko E.V., Saenko S.S., Lukyanov A.V. et al. Casereport: change of dominant strain during dual SARS-CoV-2 infection. BMC Infect. Dis. – 2021. – Vol.21(1). – 959 р.

17. Fu Y., Zhao J., Wei X., Han P., Yang L., Ren T., Zhan S., Li L. Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies. // Front Public Health. – 2022. –№10. – 917732 р. doi: 10.3389/fpubh.2022.917732. PMID: 35928479; PMCID: PMC9343737.